Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Aeterna Zentaris stock opened at $1.95 on Monday. Aeterna Zentaris has a 1-year low of $1.36 and a 1-year high of $3.38. The company has a market cap of $9.48 million, a PE ratio of -0.57 and a beta of 1.57. The stock’s 50 day moving average price is $1.97 and its 200 day moving average price is $1.89.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.19). Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%. The business had revenue of $0.12 million during the quarter.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.